Last €2.53 EUR
Change Today +0.028 / 1.12%
Volume 0.0
IM3 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:09 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

immunomedics inc (IM3) Snapshot

Open
€2.53
Previous Close
€2.50
Day High
€2.53
Day Low
€2.53
52 Week High
10/2/13 - €5.34
52 Week Low
05/9/14 - €2.19
Market Cap
235.8M
Average Volume 10 Days
575.0
EPS TTM
--
Shares Outstanding
93.1M
EX-Date
03/14/02
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOMEDICS INC (IM3)

immunomedics inc (IM3) Related Bloomberg News

View More Bloomberg News

immunomedics inc (IM3) Related Businessweek News

No Related Businessweek News Found

immunomedics inc (IM3) Details

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer. The company’s antibody-drug conjugate (ADC) products comprise IMMU-132, an ADC that contains SN-38, which is in Phase 2 clinical development focusing on triple-negative breast cancer and colorectal cancer; and IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II clinical development for the treatment of metastatic colorectal cancer. Its early-stage products include Veltuzumab, a humanized monoclonal antibody, which is in Phase 2 study; Milatuzumab, an anti-CD74 antibody for the treatment of graft-versus-host disease that has completed initial Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL, which is in Phase 1/2 clinical trial; Milatuzumab-Doxorubicin, a clinically-evaluated agent that is in Phase 1 dose-escalation trial; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone in patients. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has strategic partnership with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

120 Employees
Last Reported Date: 08/25/14
Founded in 1982

immunomedics inc (IM3) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $598.0K
Founder, Chairman of the Board, Chief Medical...
Total Annual Compensation: $564.7K
Consultant
Total Annual Compensation: $315.4K
Compensation as of Fiscal Year 2013.

immunomedics inc (IM3) Key Developments

Immunomedics Seeks Acquisitions

Immunomedics Inc. (NasdaqGM:IMMU) has filed a shelf registration in the amount of $130 million. Immunomedics said, "We intend to use the net proceeds from the sale of the securities we offer by this prospectus for general corporate purposes, which may include, among other things research and development of product candidates, additions to working capital, the redemption or repurchase of outstanding equity, the repayment of indebtedness and the expansions of our business through internal growth or acquisitions."

Immunomedics Inc. Announces Consolidated Earnings Results for Fourth Quarter and Full Year Ended June 30, 2014; Provides Planned Activities for its Clinical Pipeline

Immunomedics Inc. announced consolidated earnings results for fourth quarter and full year ended June 30, 2014. For the quarter, the company reported total revenues of $1,186,993, operating loss of $11,891,997, loss before income tax expense of $11,866,936, net loss attributable to company of $11,846,781 or $0.13 per basic and diluted share compared to the total revenues of $1,361,962, operating loss of $7,677,463, loss before income tax expense of $7,686,071, net loss attributable to company of $7,682,929 or $0.09 per basic and diluted share for the same quarter a year ago. For the year, the company reported total revenues of $9,041,605, operating loss of $35,580,241, loss before income tax expense of $35,523,387, net loss attributable to company of $35,425,826 or $0.42 per basic and diluted share compared to the total revenues of $4,961,997, operating loss of $30,792,498, loss before income tax expense of $11,442,214, net loss attributable to company of $11,381,523 or $0.15 per basic and diluted share for the previous year. The increase in net loss of $24.0 million in fiscal 2014 resulted primarily from the $16.7 million arbitration settlement and $2.6 million insurance proceeds, both received during the previous year, and $5.3 million of increased research and development spending in fiscal 2014. The company highlighted recent key developments and planned activities for its clinical pipeline. Epratuzumab: The two Phase III EMBODY trials evaluating epratuzumab in patients with moderate or severe systemic lupus erythematosus (SLE) are fully enrolled. Top-line results from these studies will be available in the first half of calendar year 2015. Clivatuzumab tetraxetan: Final results from the randomized Phase Ib study of fractionated yttrium-90-labeled clivatuzumab tetraxetan in patients with pancreatic cancer having 2 or more prior therapies were presented at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer: Innovations in Research and Treatment and at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Immunomedics Inc. to Report Q4, 2014 Results on Aug 25, 2014

Immunomedics Inc. announced that they will report Q4, 2014 results on Aug 25, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM3:GR €2.53 EUR +0.028

IM3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IM3.
View Industry Companies
 

Industry Analysis

IM3

Industry Average

Valuation IM3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.3x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOMEDICS INC, please visit www.immunomedics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.